KMT2A and acute myeloid leukemia: To assess the therapeutic efficacy of FP54 in treating AML in vivo, we performed bone marrow (BM) transplantation in NSG (NOD-SCID IL2Rγnull) mice using the MA9.3Ras AML cells, which were generated by sequential retroviral expression of MLL-AF9 and NrasG12D cDNA into human umbilical cord blood CD34+ cells (34, 35).